Effect of treatment with nasal continuous positive airway pressure on ventilatory response to hypoxia and hypercapnia in patients with sleep apnea syndrome

Lucia Spicuzza, Luciano Bernardi, Rossella Balsamo, Nicola Ciancio, Riccardo Polosa, Giuseppe Di Maria

Research output: Contribution to journalArticle

43 Citations (Scopus)

Abstract

Background: The increase in peripheral chemoreflex sensitivity in patients with obstructive sleep apnea (OSA) is associated with activation of autonomic nervous system and hemodynamic responses. Nasal CPAP (nCPAP) is an effective treatment for OSA, but little is known on its effect on chemoreflex sensitivity. Objectives: To assess the effect of nCPAP treatment or placebo (sham nCPAP) on ventilatory control in patients with OSA. Setting: Sleep laboratory of Azienda Ospedaliera Garibaldi. Patients: Twenty-five patients with moderate-to-severe OSA. Design and measurements: Patients were randomly assigned to either therapeutic nCPAP (use of optimal pressure, n = 15) or sham nCPAP (suboptimal pressure of 1 to 2 cm H2O, n = 10) in a double-blind fashion and treated for 1 month. A rebreathing test to assess ventilatory response to normocapnic hypoxia and normoxic hypercapnia was performed at basal condition and after 1 month of treatment. Results: The use of therapeutic nCPAP or sham nCPAP did not affect daytime percentage of arterial oxygen saturation (Sao 2%) or end-tidal Pco2. The normocapnic hypoxic ventilatory response was reduced after 1 month of treatment with nCPAP (the slope was 1.08 ± 0.02 L/min/Sao2% at basal condition and 0.53 ± 0.07 L/min/Sao2% after 1 month of treatment, p = 0.008) [mean ± SD], but not in patients treated with sham nCPAP (slope, 0.83 ± 0.09 L/min/Sao2% and 0.85 ± 0.19 L/min/Sao2% at basal condition and after 1 month, respectively). The normoxic hypercapnic ventilatory response remained unchanged after 1 month in both groups. No changes in ventilatory response to either hypoxia or hypercapnia were observed after a single night of nCPAP treatment. Conclusion: The ventilatory response to hypoxia is reduced during regular treatment, but not after short-term treatment, with nCPAP. Readjusted peripheral oxygen chemosensitivity during nCPAP treatment may be a side effect of both reduced sympathetic activity and increased baroreflex activity, or a possible continuous positive airway pressure-related mechanism leading to a reduced activation of autonomic nervous system per se.

Original languageEnglish
Pages (from-to)774-779
Number of pages6
JournalChest
Volume130
Issue number3
DOIs
Publication statusPublished - Sep 2006

Fingerprint

Continuous Positive Airway Pressure
Hypercapnia
Sleep Apnea Syndromes
Nose
Obstructive Sleep Apnea
Therapeutics
Autonomic Nervous System
Hypoxia
Oxygen
Pressure
Baroreflex
Therapeutic Uses
Sleep
Hemodynamics
Placebos

Keywords

  • Hypercapnia
  • Hypoxia
  • Nasal continuous positive airway pressure
  • Obstructive sleep apnea
  • Ventilatory response

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Effect of treatment with nasal continuous positive airway pressure on ventilatory response to hypoxia and hypercapnia in patients with sleep apnea syndrome. / Spicuzza, Lucia; Bernardi, Luciano; Balsamo, Rossella; Ciancio, Nicola; Polosa, Riccardo; Di Maria, Giuseppe.

In: Chest, Vol. 130, No. 3, 09.2006, p. 774-779.

Research output: Contribution to journalArticle

Spicuzza, Lucia ; Bernardi, Luciano ; Balsamo, Rossella ; Ciancio, Nicola ; Polosa, Riccardo ; Di Maria, Giuseppe. / Effect of treatment with nasal continuous positive airway pressure on ventilatory response to hypoxia and hypercapnia in patients with sleep apnea syndrome. In: Chest. 2006 ; Vol. 130, No. 3. pp. 774-779.
@article{fdcb3bbf13ed4b1484856b7ac43d7dac,
title = "Effect of treatment with nasal continuous positive airway pressure on ventilatory response to hypoxia and hypercapnia in patients with sleep apnea syndrome",
abstract = "Background: The increase in peripheral chemoreflex sensitivity in patients with obstructive sleep apnea (OSA) is associated with activation of autonomic nervous system and hemodynamic responses. Nasal CPAP (nCPAP) is an effective treatment for OSA, but little is known on its effect on chemoreflex sensitivity. Objectives: To assess the effect of nCPAP treatment or placebo (sham nCPAP) on ventilatory control in patients with OSA. Setting: Sleep laboratory of Azienda Ospedaliera Garibaldi. Patients: Twenty-five patients with moderate-to-severe OSA. Design and measurements: Patients were randomly assigned to either therapeutic nCPAP (use of optimal pressure, n = 15) or sham nCPAP (suboptimal pressure of 1 to 2 cm H2O, n = 10) in a double-blind fashion and treated for 1 month. A rebreathing test to assess ventilatory response to normocapnic hypoxia and normoxic hypercapnia was performed at basal condition and after 1 month of treatment. Results: The use of therapeutic nCPAP or sham nCPAP did not affect daytime percentage of arterial oxygen saturation (Sao 2{\%}) or end-tidal Pco2. The normocapnic hypoxic ventilatory response was reduced after 1 month of treatment with nCPAP (the slope was 1.08 ± 0.02 L/min/Sao2{\%} at basal condition and 0.53 ± 0.07 L/min/Sao2{\%} after 1 month of treatment, p = 0.008) [mean ± SD], but not in patients treated with sham nCPAP (slope, 0.83 ± 0.09 L/min/Sao2{\%} and 0.85 ± 0.19 L/min/Sao2{\%} at basal condition and after 1 month, respectively). The normoxic hypercapnic ventilatory response remained unchanged after 1 month in both groups. No changes in ventilatory response to either hypoxia or hypercapnia were observed after a single night of nCPAP treatment. Conclusion: The ventilatory response to hypoxia is reduced during regular treatment, but not after short-term treatment, with nCPAP. Readjusted peripheral oxygen chemosensitivity during nCPAP treatment may be a side effect of both reduced sympathetic activity and increased baroreflex activity, or a possible continuous positive airway pressure-related mechanism leading to a reduced activation of autonomic nervous system per se.",
keywords = "Hypercapnia, Hypoxia, Nasal continuous positive airway pressure, Obstructive sleep apnea, Ventilatory response",
author = "Lucia Spicuzza and Luciano Bernardi and Rossella Balsamo and Nicola Ciancio and Riccardo Polosa and {Di Maria}, Giuseppe",
year = "2006",
month = "9",
doi = "10.1378/chest.130.3.774",
language = "English",
volume = "130",
pages = "774--779",
journal = "Chest",
issn = "0012-3692",
publisher = "Elsevier Inc.",
number = "3",

}

TY - JOUR

T1 - Effect of treatment with nasal continuous positive airway pressure on ventilatory response to hypoxia and hypercapnia in patients with sleep apnea syndrome

AU - Spicuzza, Lucia

AU - Bernardi, Luciano

AU - Balsamo, Rossella

AU - Ciancio, Nicola

AU - Polosa, Riccardo

AU - Di Maria, Giuseppe

PY - 2006/9

Y1 - 2006/9

N2 - Background: The increase in peripheral chemoreflex sensitivity in patients with obstructive sleep apnea (OSA) is associated with activation of autonomic nervous system and hemodynamic responses. Nasal CPAP (nCPAP) is an effective treatment for OSA, but little is known on its effect on chemoreflex sensitivity. Objectives: To assess the effect of nCPAP treatment or placebo (sham nCPAP) on ventilatory control in patients with OSA. Setting: Sleep laboratory of Azienda Ospedaliera Garibaldi. Patients: Twenty-five patients with moderate-to-severe OSA. Design and measurements: Patients were randomly assigned to either therapeutic nCPAP (use of optimal pressure, n = 15) or sham nCPAP (suboptimal pressure of 1 to 2 cm H2O, n = 10) in a double-blind fashion and treated for 1 month. A rebreathing test to assess ventilatory response to normocapnic hypoxia and normoxic hypercapnia was performed at basal condition and after 1 month of treatment. Results: The use of therapeutic nCPAP or sham nCPAP did not affect daytime percentage of arterial oxygen saturation (Sao 2%) or end-tidal Pco2. The normocapnic hypoxic ventilatory response was reduced after 1 month of treatment with nCPAP (the slope was 1.08 ± 0.02 L/min/Sao2% at basal condition and 0.53 ± 0.07 L/min/Sao2% after 1 month of treatment, p = 0.008) [mean ± SD], but not in patients treated with sham nCPAP (slope, 0.83 ± 0.09 L/min/Sao2% and 0.85 ± 0.19 L/min/Sao2% at basal condition and after 1 month, respectively). The normoxic hypercapnic ventilatory response remained unchanged after 1 month in both groups. No changes in ventilatory response to either hypoxia or hypercapnia were observed after a single night of nCPAP treatment. Conclusion: The ventilatory response to hypoxia is reduced during regular treatment, but not after short-term treatment, with nCPAP. Readjusted peripheral oxygen chemosensitivity during nCPAP treatment may be a side effect of both reduced sympathetic activity and increased baroreflex activity, or a possible continuous positive airway pressure-related mechanism leading to a reduced activation of autonomic nervous system per se.

AB - Background: The increase in peripheral chemoreflex sensitivity in patients with obstructive sleep apnea (OSA) is associated with activation of autonomic nervous system and hemodynamic responses. Nasal CPAP (nCPAP) is an effective treatment for OSA, but little is known on its effect on chemoreflex sensitivity. Objectives: To assess the effect of nCPAP treatment or placebo (sham nCPAP) on ventilatory control in patients with OSA. Setting: Sleep laboratory of Azienda Ospedaliera Garibaldi. Patients: Twenty-five patients with moderate-to-severe OSA. Design and measurements: Patients were randomly assigned to either therapeutic nCPAP (use of optimal pressure, n = 15) or sham nCPAP (suboptimal pressure of 1 to 2 cm H2O, n = 10) in a double-blind fashion and treated for 1 month. A rebreathing test to assess ventilatory response to normocapnic hypoxia and normoxic hypercapnia was performed at basal condition and after 1 month of treatment. Results: The use of therapeutic nCPAP or sham nCPAP did not affect daytime percentage of arterial oxygen saturation (Sao 2%) or end-tidal Pco2. The normocapnic hypoxic ventilatory response was reduced after 1 month of treatment with nCPAP (the slope was 1.08 ± 0.02 L/min/Sao2% at basal condition and 0.53 ± 0.07 L/min/Sao2% after 1 month of treatment, p = 0.008) [mean ± SD], but not in patients treated with sham nCPAP (slope, 0.83 ± 0.09 L/min/Sao2% and 0.85 ± 0.19 L/min/Sao2% at basal condition and after 1 month, respectively). The normoxic hypercapnic ventilatory response remained unchanged after 1 month in both groups. No changes in ventilatory response to either hypoxia or hypercapnia were observed after a single night of nCPAP treatment. Conclusion: The ventilatory response to hypoxia is reduced during regular treatment, but not after short-term treatment, with nCPAP. Readjusted peripheral oxygen chemosensitivity during nCPAP treatment may be a side effect of both reduced sympathetic activity and increased baroreflex activity, or a possible continuous positive airway pressure-related mechanism leading to a reduced activation of autonomic nervous system per se.

KW - Hypercapnia

KW - Hypoxia

KW - Nasal continuous positive airway pressure

KW - Obstructive sleep apnea

KW - Ventilatory response

UR - http://www.scopus.com/inward/record.url?scp=33748861254&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748861254&partnerID=8YFLogxK

U2 - 10.1378/chest.130.3.774

DO - 10.1378/chest.130.3.774

M3 - Article

C2 - 16963674

AN - SCOPUS:33748861254

VL - 130

SP - 774

EP - 779

JO - Chest

JF - Chest

SN - 0012-3692

IS - 3

ER -